

# **Detour**<sup>®</sup> Bypass

Preserving long-term kidney function and improving patients' quality-of-life

A patient guide to learn more about this effective therapeutic option and suitable alternative





## Inside this guide

A sterile and safe alternative treatment to standard urinary tract diversion	.3
Highly effective and minimally invasive	.4
Well-tolerated material	.6
Long-term implantation	.6
Durability	.6
Quality of life improved	.7
Barely visible	.8
Fast recovery	.8
Having Detour implant	.9
Which patients can be candidates for the placement of Detour?	.9
Prerequisites for implantation	.9
Detour placement	.9
What is the optimal aftercare?1	10
References 1	1

## A sterile and safe alternative treatment to standard urinary tract diversion

In healthy people, the urine produced by the kidneys flows into the bladder **via the ureters** (Figure 1).

If this drainage is impaired, the urine is retained in the kidney, and this can be both dangerous and painful.

Conventionally, urologists **alleviate chronic urine retention** as **standard** with **renal catheters** (nephrostomy drains that are left in place through the skin, often permanently) which drain the urine into a bag, or with **ureteral stents** (small internal tubes). Both forms of treatment are frequently associated with patient's discomfort and complications<sup>1-5</sup> (Table 1), moreover in case of long-term treatment.

# Surgeons striving for patient's comfort have developed a suitable solution: **Detour**





## Highly effective and minimally invasive

Detour is an **internal bypass** that re-establishes the connection for urine drainage between the kidney and the bladder.

It is implanted in the flank underneath the skin, and customised to the physique of the patient.<sup>1,6</sup>



The straightforward operation for Detour insertion can be performed on one or both kidneys.<sup>2,3,6</sup> This device has been successfully used in many patients, and even on transplanted kidneys.<sup>8</sup>



The Detour bypass is a clinically safe and highly effective alternative for patients with still functioning bladder and kidney, who required permanent nephrostomy or palliative ureteral stenting.<sup>3-6,9-11</sup>

#### Standard urinary diversion systems versus Detour:

## Biocompatible material<sup>12</sup>

The Detour system consists of two biomaterial layers: a silicone tube reinforced with a polyester sheath:

- A smooth<sup>2</sup> inner **silicone tube** through which the urine drains safely; one end is inserted in the kidney and the other end goes into the bladder.<sup>6-8</sup> Only the silicone is in contact with urine, thus reducing the risk of encrustation. Indeed, silicone is biocompatible and quite resistant to encrustation.<sup>\*,2,12</sup>
- Between the kidney and the bladder, this silicone tube is enclosed in a porous **polyester sheath** whose grooved surface readily becomes selffixated in the surrounding tissues, and in this way holds the implant securely in the desired position.<sup>2,6,7</sup> This inert material allows limiting inflammatory reactions.<sup>2</sup>

\*Encrustation means a mineral deposit that may form inside drainage tubes after long-term contact with urine.

## Long-term implantation

### Durability

Unlike renal catheters that have to be changed every 1 - 3 months or ureteral stents whose replacement is recommended about every 3 - 12 months to avoid complication,<sup>13</sup> depending on patient's risk profile, Detour is a long-term ureter replacement.<sup>6-8</sup>

Clinical data show an average implantation duration of about 2 years (23 months). In some patients, experience already dates back more than 10 years, which means for the patient that Detour has significantly increased his quality of life.<sup>8</sup>

The long-term reliability of Detour bypass has also been demonstrated even in difficult cases such as renal transplantation.<sup>8</sup>



Well tolerated underneath the skin,<sup>3</sup> Detour improves patient quality of life:

AMMIMUM

- Subcutaneous urine drainage with Detour makes life easier: there is no constraining leg bag, there is no risk of displacement; regular changes of ureteral stents or renal catheters are also unnecessary, as are the associated visits to the doctor, while the risk of infection is reduced.<sup>3-6,9-11</sup>
- This creates more time and new opportunities for an active social life: quality of life and social reintegration are improved significantly in patients with Detour.<sup>9</sup>

#### **Barely visible**

The Detour implant is barely visible after implantation. Only in thin people can a hint of the track be seen and may be palpable,<sup>1</sup> but doesn't cause discomfort.<sup>4</sup> Due to the minimally invasive surgery, only minor scars remain visible in the long-term: one in the flank and another in the lower abdomen, which correspond to the two small skin incisions that were necessary to position the implant correctly.<sup>1,3,4</sup>

#### Fast recovery

Following the operation, it takes the body a few days to get used to the new situation.<sup>7,4</sup>

## Having the Detour bypass

## Which patients can be candidates for the placement of Detour?

Selected patients:1,2,5-8,10 (Figure 2)

- With an impassable ureteral obstruction (caused by a benign or a tumoral disease) and with permanent nephrostomy,
- Or with complete disruption of the ureter, in whom repeat stenting or ureteral reconstruction is not possible or not indicated (e.g., transplanted kidneys with failed endoscopic and open procedures),
- Or with failure or intolerance of ureteral stents.





#### Freedom from urinary infection;

- · Adequate renal function;
- Intact urinary bladder with adequate storage capacity;
- If adult, age does not matter

#### **Detour placement**

Detour implantation represents a minimally invasive technique that is accessible to surgeons performing percutaneous surgery. The radiopaque ring of Detour enables an easy identification during its placement.

Under general anesthesia, Detour is placed in the kidney through a small incision of the flank. Detour bypass is cut to the correct length for the patient. Then it is tunnelled underneath the skin and sutured into the bladder after having accessed the bladder through another small incision in the lower abdomen.<sup>6.7</sup>

A good operation also relies on conscientious aftercare.<sup>9</sup>

### What is the optimal aftercare?

During the first half-year after implantation, follow-up monitoring should be given to patients one month after intervention, then 3 and 6 months after. After that, biannual controls shall be sufficient, depending on the case.<sup>6</sup>

The most important thing is to attend follow-up appointments. If a problem occurs, for example a urinary tract infection, then please go to the doctor immediately!

## General preventive diet measures are also advised:

#### Drinks:

 Patients must drink enough water so that the Detour bypass is flushed well. This also dilutes your urine and reduces the risk of stones that could form around the bypass.<sup>14</sup>

#### Food:

Tips for a urinary stone diet<sup>14,15</sup>:

- Limit your intake of animal proteins, salt and rapid-absorption sugars.
- Eat fruit and vegetables which contain alkaline minerals such as potassium.
- It is essential to have a well-balanced diet, avoiding too many calories.



## References

1) Kimuli M, Sciberras J, Lloyd S. (2012). Extra-Anatomic Urinary Drainage for Urinary Obstruction. In: Chronic Kidney Disease. Gooz M (Ed.), InTech, Rijeka, Croatia, 281-296.

2) Nouaille A, Descazeaud A, Desgrandchamps F, Bazin D, Daudon M, Masson Lecomte A, Mongiat-Artus P and Meria P. (2021). Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstruction. Prog Urol, 31(6), 348-356.

**3)** Watson G. (2017). Detour Extra-Anatomical Ureteric Stent. In: Ureteric Stenting. Kulkarni R (Ed.). John Wiley & Sons, Ltd, Oxford, UK, 161-174.

4) Wrona A, Zgajewski J, Kopec N, Chodor D, Kopcza P and Klekot S. (2017). Subcutaneous pyelovesical bypass - Detour bypass - as a solution for ureteric obstruction. Cent European J Urol, 70, 429-433.

5) Chong JJY, Kum F, Hadjipavlou M, Mahmalji W, Hale J, Dickinson A and Glass J. (2019). Extra-Anatomic Stents in Ureteric Obstruction: Our Experience. J Endourol, 33(3), 242-247.

6) Desgrandchamps F, Leroux S, Ravery V, Bochereau G, Menut P, Meria P, Ballanger P, Teillac P. (2007). Subcutaneous pyelovesical bypass as replacement for standard percutaneous nephrostomy for palliative urinary diversion: prospective evaluation of patient's quality of life. J Endourol, 21(2):173-6.

7) Lloyd SN, Tirukonda P, Biyani CS, Wah TM, Irving HC. (2007). The Detour extra-anatomic stent--a permanent solution for benign and malignant ureteric obstruction? Eur Urol, 52(1):193-8.

8) Muller CO, Meria P, Desgrandchamps F. (2011). Long-term outcome of subcutaneous pyelovesical bypass in extended ureteral stricture after renal transplantation. J Endourol, 25(8):1389-92.

9) Janitzky A, Borski J, Porsch M, Wendler JJ, Baumunk D, Liehr UB. and Schostak M. (2014). Long-term results for subcutaneous Detour<sup>®</sup> prosthesis in ureteral obstruction - Experience of implantation, aftercare and management of complications. J Urol, 191(45), e89. [Abstract].

10) Kartalas-Goumas I, Tondelli E, Talso M and Zanetti G. (2019). Extranatomical urinary diversion with the Detour<sup>™</sup> for the treatment of complex ureteric stenosis: Preliminary experience with 19 cases. Eur Urol, 18S(1), e1487-e1487; 1098, Poster session, 34th European Association of Urology Annual Congress, EAU19, March 15 to 19, 2019, Barcelona, Spain. [Abstract].

11) Goumas I, Jeppesen S, Pedersen T, Diatchikhine M, Popiolek M, Wrona A and Lund L. (2020). Can Extra Anatomical Urinary Diversion (EAUD) be used safely in elderly cancer patients? J Urol, 203(4S), e595-e596; Poster, MP41-02, 2020 American Urological Association Virtual Education Experience, AUA Live 2020, 27-28 June 2020. [Abstract].

**12)** Denstedt JD, Wollin TA and Reid G. (1998). Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. J Endourol, 12(6), 493-500.

**13)** Damiano R, Oliva A, Esposito C, De Sio M, Autorino R and D'Armiento M. (2002). Early and late complications of double pigtail ureteral stent. Urol Int, 69(2), 136-140.

14) Wilcox CR, Whitehurst LA, Cook P and Somani BK. (2020). Kidney stone disease: an update on its management in primary care. Br J Gen Pract, 70(693), 205-206.

**15)** Ferraro PM, Bargagli M, Trinchieri A and Gambaro G. (2020). Risk of Kidney Stones: Influence of Dietary Factors, Dietary Patterns, and Vegetarian-Vegan Diets. Nutrients, 12(3).



## You can play an active role in your health care by talking to your doctor.





Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology. Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S.  $\odot$  [2021.07.] All rights reserved. Coloplast A/S, 3050 Humleback, Denmark. PM-14543